Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement

被引：3
作者：
Liang, Long [1 ]
Mao, Mian [2 ]
Wu, Lei [1 ]
Chen, Taiyu [3 ]
Lyu, Jiahua [1 ]
Wang, Qifeng [1 ]
Li, Tao [1 ]
机构：
[1] Univ Elect Sci & Technol China, Sch Med, Dept Radiat Oncol, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr,Radiat, 55,4th Sect Renmin South Rd, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Hosp & Inst, Dept Pharm,Sichuan Canc Ctr, Chengdu, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2021年 / 14卷
关键词：
lung squamous cell carcinoma; EML4-ALK rearrangement; alectinib; lorlatinib; SBRT; CRIZOTINIB; CANCER; 1ST;
D O I：
10.2147/OTT.S335736
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
EML4-ALK rearrangement is common in lung adenocarcinoma. The ALK inhibitors remarkably inhibit lung adenocarcinoma and reveal long-term beneficial effects in several patients. Advanced genetic testing technology reveals that EML4-ALK rearrangement has been observed in patients with lung squamous cell carcinoma. In the present study, we report a case of a 53-year-old patient with EML4-ALK rearranged in lung squamous carcinoma; PET/ CT scan revealed brain and multiple bone metastases. First-line ALK-TKI combined with local stereotactic body radiation therapy indicated progression-free survival of 9 months. After progressive disease, treatment was switched to lorlatinib, with little efficacy and a total overall survival of 11 months. The emergence of drug resistance revealed that the genetic test result was EML4-ALK fusion (V3a/b variants), indicating a poor prognosis. In this study, we analyzed the treatment efficacy of ALK inhibitors and provided a research basis for the treatment of EML4-ALK rearranged in lung squamous cell carcinoma patients.
引用
收藏
页码：5385 / 5389
页数：5
相关论文
共 22 条
  • [1] EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer
    Christopoulos, Petros
    Endris, Volker
    Bozorgmehr, Farastuk
    Elsayed, Mei
    Kirchner, Martina
    Ristau, Jonas
    Buchhalter, Ivo
    Penzel, Roland
    Herth, Felix J.
    Heussel, Claus P.
    Eichhorn, Martin
    Muley, Thomas
    Meister, Michael
    Fischer, Juergen R.
    Rieken, Stefan
    Warth, Arne
    Bischoff, Helge
    Schirmacher, Peter
    Stenzinger, Albrecht
    Thomas, Michael
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (12) : 2589 - 2598
  • [2] NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Aisner, Dara L.
    Wood, Douglas E.
    Akerley, Wallace
    Bauman, Jessica
    Chang, Joe Y.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dobelbower, Michael
    Govindan, Ramaswamy
    Gubens, Matthew A.
    Hennon, Mark
    Horn, Leora
    Lackner, Rudy P.
    Lanuti, Michael
    Leal, Ticiana A.
    Lilenbaum, Rogerio
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Sandip, P.
    Reckamp, Karen
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Stevenson, James
    Swanson, Scott J.
    Tauer, Kurt
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (07): : 807 - 821
  • [3] The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
    Friboulet, Luc
    Li, Nanxin
    Katayama, Ryohei
    Lee, Christian C.
    Gainor, Justin F.
    Crystal, Adam S.
    Michellys, Pierre-Yves
    Awad, Mark M.
    Yanagitani, Noriko
    Kim, Sungjoon
    Pferdekamper, AnneMarie C.
    Li, Jie
    Kasibhatla, Shailaja
    Sun, Frank
    Sun, Xiuying
    Hua, Su
    McNamara, Peter
    Mahmood, Sidra
    Lockerman, Elizabeth L.
    Fujita, Naoya
    Nishio, Makoto
    Harris, Jennifer L.
    Shaw, Alice T.
    Engelman, Jeffrey A.
    [J]. CANCER DISCOVERY, 2014, 4 (06) : 662 - 673
  • [4] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
    Gainor, Justin F.
    Dardaei, Leila
    Yoda, Satoshi
    Friboulet, Luc
    Leshchiner, Ignaty
    Katayama, Ryohei
    Dagogo-Jack, Ibiayi
    Gadgeel, Shirish
    Schultz, Katherine
    Singh, Manrose
    Chin, Emily
    Parks, Melissa
    Lee, Dana
    DiCecca, Richard H.
    Lockerman, Elizabeth
    Huynh, Tiffany
    Logan, Jennifer
    Ritterhouse, Lauren L.
    Le, Long P.
    Muniappan, Ashok
    Digumarthy, Subba
    Channick, Colleen
    Keyes, Colleen
    Getz, Gad
    Dias-Santagata, Dora
    Heist, Rebecca S.
    Lennerz, Jochen
    Sequist, Lecia V.
    Benes, Cyril H.
    Iafrate, A. John
    Mino-Kenudson, Mari
    Engelman, Jeffrey A.
    Shaw, Alice T.
    [J]. CANCER DISCOVERY, 2016, 6 (10) : 1118 - 1133
  • [5] EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
    Huang, Thomas
    Engelmann, Brigitte J.
    Morgan, Rachael M.
    Absher, Kimberly J.
    Kolesar, Jill M.
    Villano, John L.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 965 - 968
  • [6] Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
    Katayama, Ryohei
    Shaw, Alice T.
    Khan, Tahsin M.
    Mino-Kenudson, Mari
    Solomon, Benjamin J.
    Halmos, Balazs
    Jessop, Nicholas A.
    Wain, John C.
    Yeo, Alan Tien
    Benes, Cyril
    Drew, Lisa
    Saeh, Jamal Carlos
    Crosby, Katherine
    Sequist, Lecia V.
    Iafrate, A. John
    Engelman, Jeffrey A.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)
  • [7] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
    Kwak, Eunice L.
    Bang, Yung-Jue
    Camidge, D. Ross
    Shaw, Alice T.
    Solomon, Benjamin
    Maki, Robert G.
    Ou, Sai-Hong I.
    Dezube, Bruce J.
    Jaenne, Pasi A.
    Costa, Daniel B.
    Varella-Garcia, Marileila
    Kim, Woo-Ho
    Lynch, Thomas J.
    Fidias, Panos
    Stubbs, Hannah
    Engelman, Jeffrey A.
    Sequist, Lecia V.
    Tan, WeiWei
    Gandhi, Leena
    Mino-Kenudson, Mari
    Wei, Greg C.
    Shreeve, S. Martin
    Ratain, Mark J.
    Settleman, Jeffrey
    Christensen, James G.
    Haber, Daniel A.
    Wilner, Keith
    Salgia, Ravi
    Shapiro, Geoffrey I.
    Clark, Jeffrey W.
    Iafrate, A. John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1693 - 1703
  • [8] Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
    Lin, Jessica J.
    Zhu, Viola W.
    Yoda, Satoshi
    Yeap, Beow Y.
    Schrock, Alexa B.
    Dagogo-Jack, Ibiayi
    Jessop, Nicholas A.
    Jiang, Ginger Y.
    Le, Long P.
    Gowen, Kyle
    Stephens, Philip J.
    Ross, Jeffrey S.
    Ali, Siraj M.
    Miller, Vincent A.
    Johnson, Melissa L.
    Lovly, Christine M.
    Hata, Aaron N.
    Gainor, Justin F.
    Iafrate, Anthony J.
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1199 - +
  • [9] First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer
    Mikes, Romana E.
    Jordan, Franziska
    Hutarew, Georg
    Studnicka, Michael
    [J]. LUNG CANCER, 2015, 90 (03) : 614 - 616
  • [10] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) : 829 - 838
123